Paul Song

CSO
​GeneQuantum Healthcare

Dr. Paul Song brings nearly 30 years of expertise in biotherapeutics drug discovery and development, with a specialization in immunology and oncology. He currently serves as the CSO at GeneQuantum Healthcare in Suzhou, China, where he oversees research and development, including new target discovery and the innovative next-generation bioconjugate (ADC) pipeline. Paul has held several prominent roles throughout his career, including CSO at Curon Biopharma in Shanghai, China, Vice President at Samsung Bioepis in Seoul, Korea, and Principal Research Scientist at Lilly Research Laboratories in Indianapolis, USA. During his tenure at Samsung Bioepis, Dr. Song played a crucial role in establishing the company as a global leader in the biosimilar industry. Additionally, he co-founded Curon Bio, a bioventure dedicated to advancing next-generation immune-oncology therapeutics. Paul holds a Ph.D. in Biology from Purdue University, USA.

Speech title & Synopsis

Innovative CMC and Manufacturing Technologies for Next-Generation Bioconjugate Drug Development

The development of ADCs is hindered by significant challenges related to CMC, including complex manufacturing processes, scalability issues, and high production costs.

GeneQuantum (GQ) has pioneered next-generation ADC technology, featuring highly stable and homogeneous ADCs through site-specific conjugation and innovative manufacturing processes using immobilized enzyme technologies within a closed system.

In my talk, I will introduce GQ's advanced technologies in conjugation, linker payload, and ADC manufacturing. These advancements address the current bottlenecks in ADC manufacturing, enabling the generation of high-quality ADCs in a cost-effective manner.